ESC Premium Access

Severe symptomatic aortic valve stenosis – TAVI the first treatment choice for all?

Event: ESC CONGRESS 2019
Topic: Noncoronary Cardiac Intervention
Session type: Symposium
Date: 3 September 2019
Time: 14:30 - 15:40

Congress Session

3 presentations in this session

What is the latest randomized evidence in TAVI field.

Speaker: Professor A. Baumbach (London, GB)
Thumbnail

Is durability still an issue?

Speaker: Professor E. Durand (Rouen, FR)
Thumbnail

NOAC, Vitamin K Antagonists, dual or single antiplatelet therapy after TAVI?

Speaker: Professor J. Mehilli (Munich, DE)
Thumbnail

3 speakers from this session

Professor Andreas Baumbach

St Bartholomews and Queen Mary University, London (United Kingdom of Great Britain & Northern Ireland)
11 presentations
1 follower

Professor Eric Durand

University Hospital of Rouen, Rouen (France)
1 presentation
0 follower

Professor Julinda Mehilli

LAKUMED Hospital Landshut-Achdorf, Munich (Germany)
26 presentations
3 followers

This platform is supported by

logo Novo Nordisk